Parameter . | OR (95% CI) . | P value . |
---|---|---|
Randomization group (control vs. intervention) | 5.35 (1.14–25.12) | 0.034 |
A1C | 1.76 (1.07–2.90) | 0.025 |
Age (years) | 1.15 (1.05–1.25) | 0.002 |
Female sex | 1.19 (0.48–2.95) | 0.704 |
Diabetes duration (years) | 1.02 (0.94–1.10) | 0.677 |
Follow-up (months) | 0.94 (0.85–1.05) | 0.287 |
Race | ||
Non-Hispanic white | — | — |
Hispanic | 1.07 (0.34–3.40) | — |
Black | 1.65 (0.33–8.11) | — |
Other | 1.18 (0.17–8.39) | 0.739 |
Parameter . | OR (95% CI) . | P value . |
---|---|---|
Randomization group (control vs. intervention) | 5.35 (1.14–25.12) | 0.034 |
A1C | 1.76 (1.07–2.90) | 0.025 |
Age (years) | 1.15 (1.05–1.25) | 0.002 |
Female sex | 1.19 (0.48–2.95) | 0.704 |
Diabetes duration (years) | 1.02 (0.94–1.10) | 0.677 |
Follow-up (months) | 0.94 (0.85–1.05) | 0.287 |
Race | ||
Non-Hispanic white | — | — |
Hispanic | 1.07 (0.34–3.40) | — |
Black | 1.65 (0.33–8.11) | — |
Other | 1.18 (0.17–8.39) | 0.739 |
Dependent variable = development of retinopathy (n = 82).